Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review.

Ma, Christopher; van Rhijn, Bram D; Jairath, Vipul; Nguyen, Tran M; Parker, Claire E; Aceves, Seema S; Furuta, Glenn T; Gupta, Sandeep K; Katzka, David A; Safroneeva, Ekaterina; Schoepfer, Alain M; Straumann, Alex; Spergel, Jonathan M; Pai, Rish K; Feagan, Brian G; Hirano, Ikuo; Dellon, Evan S; Bredenoord, Albert J (2018). Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. Clinical gastroenterology and hepatology, 16(11), 1714-1729.e3. Elsevier 10.1016/j.cgh.2018.06.005

[img]
Preview
Text
Ma ClinGastroenterolHepatol 2018.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

BACKGROUND & AIMS

Agents are being developed for treatment of eosinophilic esophagitis (EoE). However, it is not clear what outcome measures would best determine the efficacy and safety of these agents in clinical trials. We performed a systematic review of outcomes used in randomized placebo-controlled trials of EoE and we estimate the placebo response and rates of remission.

METHODS

We searched MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trials Register from inception through February 20, 2018 for randomized controlled trials of pharmacologic therapies for EoE. Efficacy outcome definitions, measurement tools, and the proportion of patients responding to placebo were collected and stratified by based on histologic, endoscopic, and patient-reported outcomes.

RESULTS

We analyzed data from 22 placebo-controlled trials, comprising 1112 patients with EoE. Ten additional active registered trials were identified. Most published trials evaluated topical corticosteroid therapy (13/22, 59.1%). Histologic outcomes measuring eosinophil density and patient-reported outcomes were reported in 21/22 published trials (95.5%). No consistently applied definitions of histologic or patient-reported response or remission were identified. Endoscopic outcomes were described in 60% (12/20) of published trials. The EoE Endoscopic Reference Score is the most commonly applied tool for describing changes in endoscopic appearance. The median histologic response to placebo was 3.7% (range 0%-31.6%) and the median rate of remission in patients given placebo was 0.0% (range 0%-11.0%). The median patient-reported response to placebo was 14.4% (range 8.6%-77.8%) and rate of remission in patients given placebo was 26.2% (range 13.2%-35.7%).

CONCLUSIONS

In a systematic review of the literature, we found that no standardized definitions of histologic, endoscopic, or patient-reported outcomes are used to determine whether pharmacologic agents produce a response or remission in patients with EoE. A core outcome set is needed to reduce heterogeneity in outcome reporting and facilitate trial interpretation and comparison of results from trials.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Safroneeva, Ekaterina

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1542-3565

Publisher:

Elsevier

Language:

English

Submitter:

Tanya Karrer

Date Deposited:

21 Jun 2018 14:15

Last Modified:

05 Dec 2022 15:14

Publisher DOI:

10.1016/j.cgh.2018.06.005

PubMed ID:

29908360

Uncontrolled Keywords:

drug endoscopy esophagus histology inflammation patient-reported outcomes placebo

BORIS DOI:

10.7892/boris.117323

URI:

https://boris.unibe.ch/id/eprint/117323

Actions (login required)

Edit item Edit item
Provide Feedback